NEW ZEALAND GAZETTE, No. 180

27 OCTOBER 2005

Health

Health Act 1956

Public Finance Act 1989

Notice of Publication of Annual Report, Including the Health and Independence Report—
Ministry of Health

Pursuant to section 44A of the Public Finance Act 1989 and section 3C of the Health Act 1956, I hereby give notice that the Ministry of Health has published its annual report for the year ended 30 June 2005, containing its financial statements, audit report and statement of responsibility for the period.

The report also includes the Health and Independence Report on the current state of public health in New Zealand.

Copies of this report can be downloaded from

www.moh.govt.nz\annualreport

Dated at Wellington this 18th day of October 2005.

ANNETTE KING, Minister of Health.

go7099

Health and Disability Services (Safety) Act 2001

Designation of Auditing Agency

Pursuant to section 32 of the Health and Disability Services (Safety) Act 2001 (“the Act”), the Director-General of Health designates Bureau Veritas Quality International (“the auditing agency”) to audit the provision or likely future provision of the following kinds of health care services:

• Hospital Care (as defined in section 4 (1) of the Act)
• Rest Home Care (as defined in section 6 (2) of the Act)
• Residential Disability Care (as defined in section 4 (1) of the Act)

This designation is subject to the following conditions:

1. The auditing agency must ensure that where it audits the provision of health care services for people with physical or sensory disabilities, intellectual disabilities, psychiatric disabilities or mental illnesses, the auditing agency observes the following:

   • For audits involving services for people with physical or sensory disabilities, a person with a pronounced physical or sensory disability must fully participate in all aspects of the audit;

   • for audits involving services for people with intellectual disabilities, a person with an intellectual disability (accompanied by a support person where necessary), or a close family or whanau member of a person with an intellectual disability must participate in all aspects of the audit; and

   • for people with psychiatric disabilities or mental illnesses, a past or present consumer of mental health services must fully participate in all aspects of the audit.

2. The auditing agency must inform the Ministry of Health immediately by way of written notice if there is any change to their accreditation status with JAS-ANZ.

3. The auditing agency must complete the accreditation process for JAS-ANZ Procedure 32 and provide the Director-General of Health with a copy of the JAS-ANZ Accreditation Schedule showing accreditation to Procedure 32 within six months of the date of designation by the Director-General of Health (or, if not within six months of designation, by any later date, as advised in writing by the Director-General of Health).

Under section 38 of the Act, this designation will expire three years after the date of this notification in the New Zealand Gazette.

Dated at Wellington this 18th day of October 2005.

K. O. POUTASI (DR), Director-General of Health.

go7136

Medicines Act 1981

Consent to the Distribution of a Changed Medicine

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicine which was referred to the Minister of Health under the provisions of section 24 (5) of the Act and is set out in the Schedule hereto:

Schedule

Product:
Lipex

Active Ingredient:
Simvastatin 10mg

Dosage Form:
Film coated tablet

New Zealand Sponsor:
Merck Sharp & Dohme (New Zealand) Limited

Manufacturers:
Merck & Co Inc, West Point, Pennsylvania, United States of America
Merck Sharp & Dohme UK Limited, Cramlington, Northumberland, United Kingdom
Merck Sharp and Dohme Australia Pty Limited, South Granville, New South Wales, Australia

Product:
Lipex

Active Ingredient:
Simvastatin 20mg

Dosage Form:
Film coated tablet

New Zealand Sponsor:
Merck Sharp & Dohme (New Zealand) Limited

Manufacturers:
Merck & Co Inc, West Point, Pennsylvania, United States of America
Merck Sharp & Dohme UK Limited, Cramlington, Northumberland, United Kingdom
Merck Sharp and Dohme Australia Pty Limited, South Granville, New South Wales, Australia